Theanine

Summary

Theanine (CHEMBL3039113) is a phase-3 clinical-stage small-molecule neuroprotective agent; indicated across 3 conditions including attention deficit-hyperactivity disorder and psychiatric disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 17
• Chemistry: 174.2 Da · C7H14N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3039113
Name	Theanine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	439378
ChEBI	CHEBI:17394
Molecular formula	C7H14N2O3
Molecular weight	174.2
InChIKey	DATAGRPVKZEWHA-YFKPBYRVSA-N

SMILES: CCNC(=O)CC[C@@H](C(=O)O)N

IUPAC name: (2S)-2-amino-5-(ethylamino)-5-oxopentanoic acid

ChEBI definition: A N5-alkylglutamine where the alkyl group is ethyl. It has been isolated from green tea.

Pharmacological roles (ChEBI): neuroprotective agent, geroprotector.

Other ChEBI roles (chemical / environmental): plant metabolite.

Also known as: L-theanine, NSC-21308, Theanine, THEANINE, L-Theanine

Patent coverage: 7,590 distinct patent families (14,154 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 14,153 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
attention deficit-hyperactivity disorder	2	MONDO:0007743	EFO:0003888
psychiatric disorder	0	MONDO:0002025	MONDO:0002025

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
Not specified	9
EARLY_PHASE1	3
PHASE4	2
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00981955	PHASE4	COMPLETED	The Effects of Caffeine and L-theanine Both Alone and in Combination on Cerebral Blood Flow, Cognition and Mood
NCT04056650	PHASE4	TERMINATED	Assessing the Effectiveness of an N-of-1 Platform Using Study of Cognitive Enhancers
NCT00372151	PHASE3	COMPLETED	L-Theanine in the Management of Schizophrenia
NCT00291070	PHASE2	COMPLETED	Effects of L-Theanine in Boys With ADHD
NCT05808595	PHASE2	COMPLETED	The Safety and Efficacy of AlphaWave® L-Theanine on Adults Who Experience Moderate Stress on a Regular Basis
NCT07220447	EARLY_PHASE1	RECRUITING	L-Theanine to Support Relaxation and Mood for Cancer Patients in Surveillance
NCT03533556	EARLY_PHASE1	COMPLETED	Effects of L-theanine and Caffeine on Attention and Attention-related Brain Activity of Children With Attention Deficit Hyperactivity Disorder
NCT04749745	EARLY_PHASE1	COMPLETED	Effects of L-theanine on Motor Cortex Excitability in Healthy Subjects: A Paired-Pulse TMS Study
NCT07004023	Not specified	RECRUITING	A Clinical Trial to Assess the Efficacy of a Single-dose of AlphaWave® L-Theanine on Cognitive Function in Healthy Adults With Moderate Stress
NCT07189442	Not specified	RECRUITING	L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD
NCT01361204	Not specified	COMPLETED	Anti-stress Effect of Theanine on Students During Long-term Pharmacy Practices
NCT01831986	Not specified	UNKNOWN	Pregnenolone and L-theanine Augmentation in the Treatment for Schizophrenia and Schizoaffective Disorders
NCT01851122	Not specified	COMPLETED	The Effect of the Amino Acid L-Theanine on Alertness and Vigilance
NCT02298530	Not specified	COMPLETED	Tea Components, Mental Stress and Blood Pressure
NCT02770105	Not specified	COMPLETED	Theanine and Caffeine on Neurophysiology of Attention
NCT05450952	Not specified	TERMINATED	Evaluate the Effects of a Theanine Formulation on Stress, Burnout, Mood, and Sleep in Individuals Who Report Occasional Moderate or High Levels of Stress
NCT07268573	Not specified	COMPLETED	Effects of Caffeine and L-Theanine on Physical and Cognitive Performance in Trained Athletes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).